Evidence map›Paper›PMID 40371161›Full record

ArticleAmerican journal of cancer research2025

SEMA6B promotes thyroid tumorigenesis and chemoresistance via WNT/β-catenin signaling in response to doxorubicin.

Xiaoyu Liu, Shaoyang Cai, Yanhao Yang, Shenghui Lin, Qunxiong Pan, Xiangjin Chen

Abstract read
In one paragraph

Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaoyu LiuDepartment of Thyroid Surgery, Quanzhou First Hospital Affiliated to Fujian Medical University Quanzhou 362000, Fujian, China.
Shaoyang CaiDepartment of Thyroid Surgery, Quanzhou First Hospital Affiliated to Fujian Medical University Quanzhou 362000, Fujian, China.
Yanhao YangDepartment of Thyroid Surgery, Quanzhou First Hospital Affiliated to Fujian Medical University Quanzhou 362000, Fujian, China.
Shenghui LinSchool of Medicine, Huaqiao University Quanzhou 362021, Fujian, China.
Qunxiong PanDepartment of Thyroid Surgery, Quanzhou First Hospital Affiliated to Fujian Medical University Quanzhou 362000, Fujian, China.
Xiangjin ChenDepartment of Thyroid and Breast Surgery, The First Affiliated Hospital of Fujian Medical University Fuzhou 350005, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid cancer (THCA) is the most common endocrine malignancy and typically has a favorable prognosis. However, aggressive subtypes, particularly anaplastic thyroid carcinoma, present significant treatment challenges due to their high metastatic potential and resistance to conventional therapies. Therefore, a better understanding of the underlying mechanisms is essential for improving treatment strategies. Herein, we aimed to investigate the role of SEMA6B in THCA progression and explore its associated molecular mechanisms. Differentially expressed genes (DEGs) in THCA was screened using RNA sequencing data from paired THCA and normal tissues of 10 patients. The expression and functional role of SEMA6B in THCA were further examined using datasets from TCGA and GEO. Functional assays were conducted to evaluate the effects of SEMA6B overexpression and knockout on THCA cell proliferation.

Indexed as

chemoresistancedifferentially expressed genes (DEGs)doxorubicinprognostic biomarkerSEMA6BTHCAtumor microenvironmentWNT/β-catenin signaling

Identifiers

PMID40371161
PMCPMC12070105

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.